Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) saw a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 203,792 shares, a decrease of 28.5% from the January 15th total of 284,944 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average trading volume of 200,619 shares, the days-to-cover ratio is currently 1.0 days. Based on an average trading volume of 200,619 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the company’s shares are sold short.

Artiva Biotherapeutics Stock Up 0.3%

Shares of ARTV opened at $4.00 on Monday. The business’s 50 day moving average is $4.29 and its two-hundred day moving average is $3.62. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $7.36. The firm has a market cap of $98.20 million, a price-to-earnings ratio of -1.55 and a beta of 2.92.

Analyst Ratings Changes

ARTV has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth about $38,000. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics in the second quarter worth about $48,000. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics in the second quarter valued at about $79,000. Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $58,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.